Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2019

View Archived Issues

Integrated stress response backfires in Down syndrome

Researchers create new rat and pig models of cystic fibrosis

Novel potent OXE receptor antagonists with prolonged plasma lifetime for eosinophilic diseases

Positive data presented for WP-1220 in patients with CTCL

Novel prostate cancer bone metastasis model in humanized mice

Seviprotimut-L demonstrates safety and efficacy in part B1 of MAVIS phase III study

RQ-00490721 prevents cardiac dysfunction in mouse model of heart failure

Haplodeficiency disrupts microglial responses in AD models

Celldex begins phase Ia study with KIT inhibitor CDX-0159

DWP-212525, a next-generation therapeutic for autoimmune diseases

COR-001 suppresses hsCRP in patients with chronic kidney disease

Phase III study of vericiguat in worsening chronic heart failure meets primary endpoint

Phase III dosing defined for lixivaptan in autosomal dominant polycystic kidney disease

Scholar Rock reports preliminary PK and PD data from phase II study of SRK-015 in SMA

New ASK1/TAK1 dual kinase inhibitor for treating NASH presented

Shanghai Longwood Biopharmaceuticals divulges compounds for HBV

Preliminary clinical data on CRISPR/Cas9 gene-editing therapy CTX-001 in severe hemoglobinopathies

Enanta Pharmaceuticals patents MAP3K5 inhibitors

Adenosine A2A receptor antagonist DZD-2269 overcomes adenosine-induced immunosuppression

ORIC Pharmaceuticals presents CD73 inhibitors

Amgen identifies novel apelin receptor agonists

REVOLUTION Medicines patents mTOR inhibitors

New phase III trial in Japan studies KW-3357 to treat early-onset pre-eclampsia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...